The most significant recent advancement has been the demonstration of profound benefits in heart failure with preserved ejection fraction (HFpEF) across multiple pivotal trials, establishing GLP-1 RAs as transformative therapy for obesity-related heart failure (Table 7). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.